This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the medical space as it currently has a Zacks Industry Rank of 55 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Inovio Pharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
In fact, over the past month, current quarter estimates have narrowed from a loss of 12 cents a share to a loss of 3 cents a share, while current year estimates have narrowed from a loss of 72 cents per share to a loss of 60 cents per share. This has helped INO to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.
So, if you are looking for a decent pick in a strong industry, consider Inovio Pharmaceuticals. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
PLYMOUTH MEETING, Pa. – December 17, 2014 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Zane Yang, M.D. as Vice President, Clinical Development, Oncology. In this position, he will be responsible for advancing Inovio’s oncology portfolio of DNA immunotherapies through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio’s Chief Medical Officer.
Inovio is planning a phase III trial for its immunotherapy for a pre-cancer, known as cervical dysplasia, which met its endpoints in a recent phase II trial. The company is in or about to move into phase I trials for numerous cancers including prostate, cervical, breast, lung, head and neck and pancreatic cancers.
Dr. Yang joins Inovio from Janssen Pharmaceuticals, a unit of Johnson & Johnson, where he was Director, Oncology Medical Affairs in the U.S. Dr. Yang led the prostate cancer and solid tumor therapeutic area including development and commercialization of Zytiga®, for the treatment of metastatic castration-resistant prostate cancer. Prior to Janssen, he was Director of Global Medical Affairs and Clinical Development at Novartis Oncology, and Director of Clinical Development at Merck & Co.
Dr. J. Joseph Kim, President & CEO of Inovio, said, “Zane is a highly regarded and accomplished executive and clinical researcher whose experience in the global cancer market makes him exceptionally qualified to lead clinical development in oncology at Inovio. There’s a new wave of cancer therapeutics coming, products that enhance the body’s immune system to fight and prevent cancer. Inovio is proud to be a leader in this new paradigm of products and Dr. Yang’s leadership will play a critical role as we move forward.”
Dr. Yang, who earned his M.D. at Beijing Medical University, was a Fellow at Emory University’s Winship Cancer Institute and the Wistar Institute. Before transitioning to the pharmaceutical industry he was an associate professor at the University of Virginia Medical Center.
clinical development of Cervical Dysplasia and cancer program...He must have liked what he saw prior to joining the team. Common sense, but wont be understood by all here that post..
Sentiment: Strong Buy
Looking for accountability...it's not a bad thing..I could use some explanation of the ranting myself..
I concur, I'll make it quick,first we had the meaningless reverse split,I thought they had something up their sleve,but nothing..turns out it was just their arm. But what bothers me the most was this statement on Dwarfing, it too was meaningless and painfully proving to be empty.
For my money I'm going to find it very hard to trust statements made by a Inovio going forward" irrational exuberance" is not acceptable by the CEO So again, we have the:
And the reverse split...not very much to the plus.
A lesson to all corporate and shareholders alike.
Am I mad...you bet, I ,as you,I lost a lot of cash, or a good number of you have (unless your afraid to look) I assumed their bark and bite were in parody, it wasn't.
Am I still in,ya but my faith is tarnished .WITH ALL RESPECT...I hope the CEO learns to think more and talk less..most of the damage wasn't nessary.
are we going to have our low hanging fruit ripped off!! 16 days of mistery...(like the 12 days of Christmass)Happy holidays to all....even the bashers..
Sentiment: Strong Buy
5 analysts have set the short term price target of Inovio Pharmaceuticals Inc (NASDAQ:INO) at $22.2. The standard deviation of short term price target has been estimated at $4.32, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 29 and $19 respectively. No one sets price targets that high without knowing what their talking about...So...we wait..
No reply, no responsibility to the share holders, no respect.Now I'm wondering about how much I can trust...R/S did nothing ,dwarfing nothing,partnering did nothing.Theese are NOT my words,they'er thiers so dont focus your venom at me..maybe you better look at them..I'm NOT your problem.I'm still in but since the r/s..Down 30k..Prior to it I was up big..
Lets talk about the forbidden subject...R/S.At one point prior,we could have only gone down 2.57 or so then. Now we have 9.49 to achieve the same goal..So now ..What did the R/S do for us with out solid support to bolster the price forward.what we got was smoke and mirrors all with good intentions, but nothing to sink our teeth into..I'm still in,for some reason I'm hoping they are much better scientists then they are business men.I'll say it again,it was a fools move and now were paying for it. Down to the wire and nothing ...30 days to put up or shut up!! I don't know how you feel but I think dr. kims gun has no bullets.Id like nothing better than to be proven wrong. NO dwarfing...no low hanging fruit and not a sound.Its your money,be blind if you like..